In my role as Chief Medical Officer, I lead patient safety and quality assurance teams for our portfolio of medicines – from investigational new drug phase to established products. I am responsible for the overall benefit risk assessment of our medicines and guide our global regulatory policy and intelligence.
My passion for excellence in clinical investigation has been honed by more than 30 years as a researcher, with an extensive background in Phase 1 and 2 clinical trial design and execution, portfolio strategy, clinical operations, data management, compliance, safety reviews, global health and project management. My pharmaceutical leadership experience in exploratory research and early clinical development followed 15 years of clinical research, teaching, and practicing medicine at Massachusetts General Hospital, where I also co-led a clinical research training program for medical students and residents.
Through my rewarding roles as a physician, educator and scientist, I’ve gained deep appreciation for the needs of patients and value their insights as we continually strive to offer them life-changing medicines.
I have authored and co-authored 48 peer-reviewed papers, 27 book chapters and reviews, and served on the editorial board of the Journal of Clinical Endocrinology and Metabolism. I am a member of several scientific and medical societies including the American Medical Society, American Federation for Medical Research and the Endocrine Society.
Board certified in endocrinology, I earned a medical degree from Harvard Medical School. I completed an internship and residency in Internal Medicine, and a fellowship in Endocrinology and Metabolism at Massachusetts General Hospital before joining the faculty there. My research in the Reproductive Endocrine Unit at Mass General focused on the physiology of female reproductive disorders.
To find out more about Ann Taylor and AstraZeneca visit: https://www.astrazeneca.com/our-company/our-people/ann-e-taylor.html